Patents by Inventor Walter Newman

Walter Newman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170081413
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: May 4, 2016
    Publication date: March 23, 2017
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Publication number: 20160009808
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 14, 2016
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Patent number: 9163084
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: October 20, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Publication number: 20150086546
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: December 3, 2014
    Publication date: March 26, 2015
    Inventors: Gregory J. Larosa, Christopher J. Horvath, Walter Newman, Stephan T. Jones, Siobhan H. O'Brien, Theresa L. O'Keefe
  • Patent number: 8926971
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: January 6, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Patent number: 8846047
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
  • Publication number: 20130071381
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: June 20, 2012
    Publication date: March 21, 2013
    Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Patent number: 8227211
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: July 24, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Publication number: 20110280875
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: June 28, 2011
    Publication date: November 17, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Publication number: 20110217292
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
    Type: Application
    Filed: October 4, 2010
    Publication date: September 8, 2011
    Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
  • Patent number: 7994287
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: August 9, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Patent number: 7858326
    Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: December 28, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
  • Publication number: 20100273868
    Abstract: The invention pertains to a method of treating a condition mediated by or characterized by increased 5-lipoxygenase activity like for instance asthma in a patient suffering therefrom comprising administering to said patient a composition comprising (R)-zileuton and a pharmaceutically acceptable excipient, wherein said composition is substantially free of (S)-zileuton.
    Type: Application
    Filed: January 4, 2008
    Publication date: October 28, 2010
    Inventors: Walter Newman, Anjali Kumar, Lynne Libertine
  • Patent number: 7803904
    Abstract: The present invention relates to fusion proteins comprising a naturally occurring primate MAdCAM, wherein said naturally occurring primate MAdCAM binds ?4?7 integrin and has at least about 75% amino acid similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: September 28, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Douglas J. Ringler, Dominic Picarella, Walter Newman
  • Patent number: 7632500
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: December 15, 2009
    Assignee: Cornerstone Therapeutics, Inc.
    Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
  • Publication number: 20090285835
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
    Type: Application
    Filed: June 23, 2008
    Publication date: November 19, 2009
    Inventors: Shixin Qin, Nasim Kassam, Walter Newman
  • Publication number: 20090191192
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: September 23, 2008
    Publication date: July 30, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Patent number: 7566450
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 28, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Publication number: 20090169541
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: October 26, 2007
    Publication date: July 2, 2009
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
  • Publication number: 20090148453
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
    Type: Application
    Filed: October 15, 2007
    Publication date: June 11, 2009
    Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar